Ultime notizie per Benitec Biopharma (NASDAQ:BNTC) Azioni

Benitec Biopharma

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

Benitec Biopharma Inc

News

Management

BNTC

Benitec Biopharma's Megan Boston Confirmed As CFO

Baird analyst Brian Skorney initiates coverage on Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Outperform rating and announces Price Target of $30.

Price Target

Initiation

Analyst Ratings

Baird Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $30

Guggenheim analyst Debjit Chattopadhyay reiterates Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Buy and maintains $17 price target.

Reiteration

Guggenheim Reiterates Buy on Benitec Biopharma, Maintains $17 Price Target

Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.55) by 12.73 percent.

Earnings

Earnings Beats

Benitec Biopharma Q1 2025 GAAP EPS $(0.48) Beats $(0.55) Estimate

Offerings

Benitec Biopharma Files For Mixed Shelf Of Up To $125M

Oppenheimer initiates coverage on Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Outperform rating and announces Price Target of $35.

Oppenheimer Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $35

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Evercore ISI Group raised JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) price target from $217 to $230. Evercore ISI Group analyst Glenn Schorr maintained an Outperform rating. JPMorgan shares closed at $222.29 on Friday. <a href="https://www.benzinga.com/quote/jpm/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital cut the price target for Nurix Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) from $27 to $26. RBC Capital analyst Gregory Renza maintained an Outperform rating. Nurix Therapeutics shares closed at $23.63 on Friday. <a href="https://www.benzinga.com/quote/nrix/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel raised the price target for V.F. Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) from $21 to $25. Stifel analyst Jim Duffy maintained a Buy rating. V.F. Corporation shares closed at $20.33 on Friday. <a href="https://www.benzinga.com/quote/vfc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush raised Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) price target from $25 to $45. Wedbush analyst David Chiaverini upgraded the stock from Underperform to Neutral. Affirm shares closed at $47.08 on Friday. <a href="https://www.benzinga.com/quote/afrm/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel cut Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) price target from $13 to $11. Stifel analyst Mark Kelley maintained a Hold rating. Snap shares closed at $11.13 on Friday. <a href="https://www.benzinga.com/quote/snap/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Evercore ISI Group raised Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) price target from $68 to $71. Evercore ISI Group analyst John Pancari maintained an Outperform rating. Wells Fargo shares closed at $60.99 on Friday. <a href="https://www.benzinga.com/quote/wfc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities raised the price target for Benitec Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) from $16 to $18. JMP Securities analyst Silvan Tuerkcan maintained a Market Outperform rating. Benitec Biopharma settled at $10.86 on Friday. <a href="https://www.benzinga.com/quote/bntc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler raised Boot Barn Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) price target from $147 to $179. Piper Sandler analyst Peter Keith maintained an Overweight rating. Boot Barn shares closed at $159.36 on Friday. <a href="https://www.benzinga.com/quote/boot/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird raised the price target for Fastenal Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) from $67 to $80. Baird analyst David Manthey maintained a Neutral rating. Fastenal shares closed at $76.82 on Friday. <a href="https://www.benzinga.com/quote/fast/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen cut ArcBest Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCB#NASDAQ">ARCB</a>) price target from $131 to $114. TD Cowen analyst Jason Seidl downgraded the stock from Buy to Hold. ArcBest shares rose 1.4% to close at $105.95 on Friday. <a href="https://www.benzinga.com/quote/arcb/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying WFC stock? Here&#8217;s what analysts think:

Markets

Trading Ideas

AFRM

ARCB

BOOT

FAST

NRIX

SNAP

Wells Fargo To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday

JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Market Outperform and raises the price target from $16 to $18.

JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $18

<ul>
<li>-Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-months post-BB-301 treatment, respectively, with Subject 2 achieving a Sydney Swallow Questionnaire Score Representative of Clinically Normal Swallowing-</li>
<li>-Management plans to host a conference call on October 14 at 8:30 am EDT to discuss the interim results, details below-</li>
</ul>

Reported Saturday, Benitec Biopharma Reveals Data From Low-Dose BB-301 In Phase 1b/2a Study At World Muscle Society Congress

<h3>Gainers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock increased by 34.6% to $1.6 during Tuesday's regular session. The company's market cap stands at $2.9 million. </li>
<li>Sagimet Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMT#NASDAQ">SGMT</a>) shares rose 17.68% to $3.26. The company's market cap stands at $104.9 million. </li>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) shares rose 12.59% to $2.9. The market value of their outstanding shares is at $38.8 million. </li>
<li>Opthea (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPT#NASDAQ">OPT</a>) shares moved upwards by 12.53% to $4.58. The company's market cap stands at $704.8 million. </li>
<li>Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) stock rose 11.53% to $10.25. The company's market cap stands at $108.1 million. </li>
<li>BeyondSpring (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYSI#NASDAQ">BYSI</a>) shares rose 10.04% to $2.52. The market value of their outstanding shares is at $101.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares fell 57.4% to $0.25 during Tuesday's regular session. The company's market cap stands at $29.1 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock declined by 47.43% to $0.34. The market value of their outstanding shares is at $3.5 million. </li>
<li>Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) stock fell 40.26% to $2.08. The market value of their outstanding shares is at $99.5 million. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) shares decreased by 18.4% to $5.5. The market value of their outstanding shares is at $19.3 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares declined by 17.53% to $0.32. The market value of their outstanding shares is at $14.8 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock fell 17.46% to $0.49. The company's market cap stands at $12.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADGM

APDN

BYSI

GRTS

MNPR

NUWE

SGMT

SNSE

STTK

XAIR

12 Health Care Stocks Moving In Tuesday's Intraday Session

JMP Securities analyst Silvan Tuerkcan reiterates Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Market Outperform and maintains $16 price target.

JMP Securities Reiterates Market Outperform on Benitec Biopharma, Maintains $16 Price Target

Benitec Biopharma FY24 EPS $(5.51), Cash Runway Extended Through 2025

Biotech

General

Benitec Biopharma To Present Late Breaking Oral Abstract On BB-301 Phase 1b/2a Clinical Study At 29th Annual World Muscle Society Congress In October 2024

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Buy rating and announces Price Target of $17.

Guggenheim Initiates Coverage On Benitec Biopharma with Buy Rating, Announces Price Target of $17

Leerink Partners analyst Mani Foroohar initiates coverage on Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Outperform rating and announces Price Target of $13.

Leerink Partners Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $13

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Overweight rating and announces Price Target of $30.

Piper Sandler Initiates Coverage On Benitec Biopharma with Overweight Rating, Announces Price Target of $30

<h3>Gainers</h3>
<ul>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) stock moved upwards by 80.5% to $2.27 during Monday's regular session. The company's market cap stands at $36.6 million. </li>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) stock rose 42.17% to $12.62. The market value of their outstanding shares is at $1.7 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) stock rose 27.79% to $4.23. The market value of their outstanding shares is at $264.6 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Chromocell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) shares moved upwards by 25.68% to $2.3. The market value of their outstanding shares is at $13.5 million. </li>
<li>Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) shares moved upwards by 24.01% to $2.43. The market value of their outstanding shares is at $134.0 million. </li>
<li>Titan Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTNP#NASDAQ">TTNP</a>) shares increased by 21.74% to $8.4. The market value of their outstanding shares is at $7.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares declined by 40.1% to $0.84 during Monday's regular session. The company's market cap stands at $5.1 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock fell 22.03% to $2.69. The market value of their outstanding shares is at $2.3 million. The company's, Q2 earnings came out yesterday. </li>
<li>Heart Test Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) stock declined by 19.66% to $0.07. The company's market cap stands at $4.6 million. </li>
<li>Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) shares decreased by 16.76% to $7.7. The market value of their outstanding shares is at $65.4 million. As per the press release, Q3 earnings came out today. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) stock declined by 16.12% to $1.54. The market value of their outstanding shares is at $6.9 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) shares declined by 15.78% to $27.82. The company's market cap stands at $2.4 billion. The company's, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CCLD

CHRO

FTRE

HSCS

MGNX

NVAX

OGEN

OMGA

RNAZ

TTNP

12 Health Care Stocks Moving In Monday's Intraday Session

WIIM

Benitec Biopharma shares are trading lower after the company reported worse-than-expected Q3 GAAP EPS results and a year-over-year decrease in Q3 revenue results.

Benitec Biopharma Q3 2024 Revenue $0 Down From $54,000 YoY

Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) reported quarterly losses of $(1.64) per share which missed the analyst consensus estimate of $(0.78) by 110.26 percent.

Earnings Misses

Benitec Biopharma Q3 2024 GAAP EPS $(1.64) Misses $(0.78) Estimate

17:10 EDT Benitec Biopharma (BNTC) files $125M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving ...

Benitec Biopharma files $125M mixed securities shelf

The latest announcement is out from Benitec Biopharma ( ($BNTC) ). Benitec Biopharma Inc. has awarded discretionary bonuses to key executives for t...

Benitec Biopharma Awards Bonuses to Key Executives

Benitec GAAP EPS of -$0.48

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Benitec Biopharma (BNTC – Research Report), with a price t...

Piper Sandler Reaffirms Their Buy Rating on Benitec Biopharma (BNTC)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Steris (STE – Research Report), Benitec Biopharma (B...

Analysts Are Bullish on These Healthcare Stocks: Steris (STE), Benitec Biopharma (BNTC)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Benitec Biopharma (BNTC – Research Report), Bluebird...

Analysts Offer Insights on Healthcare Companies: Benitec Biopharma (BNTC), Bluebird Bio (BLUE) and AC Immune SA (ACIU)

Franklin Biotechnology Discovery Fund Q3 2024 Commentary

Baird initiated coverage of Benitec Biopharma (BNTC) with an Outperform rating and $30 price target The firm says Benitec's BB-301 gene therapy pac...

Benitec Biopharma initiated with an Outperform at Baird

Benitec Biopharma ( ($BNTC) ) has issued an announcement. Benitec Biopharma announced key executive appointments and compensation adjustments. Soph...

Benitec Biopharma Strengthens Leadership with Key Appointments

H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Benitec Biopharma (BNTC) with a Buy rating and $28 price target Benitec is a clini...

Benitec Biopharma initiated with a Buy at H.C. Wainwright

ACIU

ALNY

APGE

APLT

AQST

BLUE

BPMC

CNTA

GILD

HLVX

HRTX

MRNA

MRUS

NBIX

PCVX

PRAX

PTCT

RVNC

SPRY

Health Care

Press Releases

Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study

Benitec Biopharma CEO to Participate in OPMD Awareness Day Webinar

Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society

Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update

Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society

Benitec Biopharma Announces Updated Investor Webcast Information

Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference

Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update

Comments

Benitec Biopharma

Notizie

Ultime notizie per Benitec Biopharma (NASDAQ:BNTC) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO